Rajput Muhammad Ali, Ali Fizzah, Zehra Tabassum, Zafar Shahid, Kumar Gunesh
Department of Pharmacology, Multan Medical and Dental College, Multan, Pakistan.
Department of Pharmacology, Liaquat National Medical College, Karachi, Pakistan.
J Taibah Univ Med Sci. 2020 Apr 11;15(3):218-223. doi: 10.1016/j.jtumed.2020.03.003. eCollection 2020 Jun.
This study aimed to evaluate the effect of proton pump inhibitors on glycaemic control amongst diabetic patients taking anti-diabetic medications.
This randomised interventional clinical study was conducted in Basic Medical Sciences Institute, Jinnah Postgraduate Medical Centre, Karachi. Eighty patients of either sex (aged 30-60 years) with type 2 diabetes mellitus and without any known comorbidities were equally divided into two groups (i.e., = 40 for each group) and were included in this study. Group A received metformin and glimepiride, while Group B, metformin and glimepiride plus omeprazole. The efficacy of the combination medications was evaluated based on fasting blood sugar (FBS) and glycosylated haemoglobin (HbA1c) levels. Serum creatinine and liver function tests were reviewed to evaluate patients' safety profile at the initial visit and after 12 weeks.
After 12 weeks of omeprazole therapy, we observed a more significant improvement in glycaemic control in group B compared to group A based on the patients' FBS (108 ± 2.37 vs. 126 ± 2.9, P = 0.001) and HbA1c levels (7.29 ± 0.07 vs. 7.47 ± 0.04, P = 0.030).
The addition of a proton pump inhibitor along with anti-diabetic medications was considered effective in achieving better glycaemic control.
本研究旨在评估质子泵抑制剂对正在服用抗糖尿病药物的糖尿病患者血糖控制的影响。
这项随机干预性临床研究在卡拉奇真纳研究生医学中心基础医学科学研究所进行。80例年龄在30至60岁之间、患有2型糖尿病且无任何已知合并症的患者，无论性别，被平均分为两组（即每组n = 40）并纳入本研究。A组接受二甲双胍和格列美脲，而B组接受二甲双胍、格列美脲加奥美拉唑。根据空腹血糖（FBS）和糖化血红蛋白（HbA1c）水平评估联合用药的疗效。在初次就诊时和12周后复查血清肌酐和肝功能检查，以评估患者的安全性。
奥美拉唑治疗12周后，基于患者的空腹血糖（108 ± 2.37 vs. 126 ± 2.9，P = 0.001）和糖化血红蛋白水平（7.29 ± 0.07 vs. 7.47 ± 0.04，P = 0.030），我们观察到B组的血糖控制改善比A组更显著。
在抗糖尿病药物中添加质子泵抑制剂被认为有助于实现更好的血糖控制。
